Bibliography
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009;8:959-68
- Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today 2013;18:1067-73
- Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011;10:507-19
- Arrowsmith J. Trial watch: phase III and submission failures: 2007-2010. Nat Rev Drug Discov 2011;10:87
- Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat Rev Drug Discov 2011;10:328-9
- Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013;12:581-94
- Kamb A, Harper S, Stefansson K. Human genetics as a foundation for innovative drug development. Nat Biotechnol 2013;31:975-8
- Pennisi E. Genomics. ENCODE project writes eulogy for junk DNA. Science 2012;337:1159-61
- Ezkurdia I, Juan D, Rodriguez JM, et al. Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. Hum Mol Genet 2014. [Epub ahead of print]
- Rask-Andersen M, Almen MS, Schioth HB. Trends in the exploitation of novel drug targets. Nat Rev Drug Discov 2011;10:579-90
- Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012;11:401-19
- Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8
- Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999;10:1735-7
- Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-66
- Wilcox DM, Yang R, Morgan SJ, et al. Delivery of RNAi reagents in murine models of obesity and diabetes. J RNAi Gene Silencing 2007;3:225-36
- National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), and National Academies Press (U.S.). Guide for the care and use of laboratory animals. 8th edition. National Academies Press; Washington, D.C: 2011
- Vahl TP, Paty BW, Fuller BD, et al. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003;88:1772-9
- Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature reviews. Endocrinology 2012;8:728-42
- Chung HS, Oh JY, Yoo SB, et al. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice. Regul Pept 2011;170:1-3
- Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49
- Ge H, Xiong Y, Lemon B, et al. Generation of novel long-acting globular adiponectin molecules. J Mol Biol 2010;399:113-19
- Kanai M, Mullen C, Podolsky DK. Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells. Proc Natl Acad Sci USA 1998;95:178-82
- Xue Y, Shen L, Cui Y, et al. Tff3, as a novel peptide, regulates hepatic glucose metabolism. PLoS One 2013;8:e75240
- Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 2011;10:712
- Begley CG. Six red flags for suspect work. Nature 2013;497:433-4